Regeneron Pharmaceuticals, Inc.
Kathryn Guarini (Director) sells REGN shares
AI-generated summary
Director Kathryn Guarini exercised options for 400 shares of Common Stock valued at $287,748 and sold 400 shares of Common Stock for $360,000 on October 30, 2026. Following these transactions, the insider directly held 603 shares of Common Stock. The trades were executed under a Rule 10b5-1 trading plan adopted on February 13, 2026.
Key facts
- Insider
- Kathryn Guarini · Director
Rule 10b5-1 plan · adopted Feb 13, 2026
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | M · exercise or conversion of a derivativeFootnotes F1 | +400 | $719.37 | $287,748.00 | 1,003 | Direct |
| Oct 30, 2026 | S · open-market saleFootnotes F1 | −400 | $900.00 | $360,000.00 | 603 | Direct |
| Oct 30, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock Option (right to buy)Footnotes F1, F2 | −400 | $0.00 | $0.00 | 758 | Direct |
Footnotes
- F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026.
- F2 On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
More REGN filings
- 144
Filed Nov 3, 2026
- 4
Filed Nov 3, 2026
- 4
Filed Nov 3, 2026
- 144
Filed Nov 2, 2026
- 144
Filed Nov 2, 2026
- 144
Filed Nov 2, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.